Our website uses cookies to distinguish you from other users of our website to provide you with the most relevant experience by remembering your preferences and repeat visits. By clicking on ‘Accept’ you consent to our cookie policy. However, you may visit ‘Cookie Settings’ to provide a controlled consent.

Accept

News

Archive

NorthSea Therapeutics announces publication of positive results from Phase 2b ICONA clinical trial of icosabutate in biopsy-confirmed F1-F3 MASH in Journal of Hepatology Ventyx Biosciences announces presentation of data from the Phase 2 trial of allosteric TYK2 inhibitor VTX958 in Crohn’s Disease at ECCO 2025 Ventyx Biosciences highlights 2025 pipeline strategy and provides clinical updates on its NLRP3 inhibitor portfolio Phase Four Series C first closing Novadip’s NVDX3 reaches key milestones leading to IND approval from FDA to start phase 2b/3 study in cervical spine fusion Sagence AI emerges from stealth tackling economic viability of inference hardware for generative AI
Back To News
Biomodal
October 17, 2017

Biomodal

Focused on the development of tools for epigenetic analysis.

Cookie Policy Website powered by 100% renewable energy Privacy Policy